Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

NCT03867097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Raynaud Phenomenon Secondary to Systemic Sclerosis

Interventions

DRUG: Placebo IV infusion
DRUG: Iloprost Injection, for intravenous use

Sponsor

Civi Biopharma, Inc.